A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

This study has been completed.

First Received: November 12, 2004 Last Updated: November 14, 2005 History of Changes

Sponsored by:	Genentech
Information provided by:	Genentech
ClinicalTrials.gov Identifier:	NCT00096603

Purpose

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Condition	Intervention	Phase
Psoriasis	Drug: Raptiva (efalizumab)	Phase III

Study Type:	Interventional
Study Design:	Treatment, Open Label, Safety Study
Official Title:	An Open Label, Multicenter Study to Evaluate the Safety of 1.0 Mg/Kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Resource links provided by NLM:

MedlinePlus related topics: Psoriasis

Drug Information available for: Efalizumab

U.S. FDA Resources

Further study details as provided by Genentech:

Estimated Enrollment:

450

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed informed consent
Previous participation in Study ACD2600g
For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

Exclusion Criteria:

Any medical condition that, in the judgment of the investigator, would jeopardize the subject’s safety following exposure to Efalizumab

Contacts and Locations

No Contacts or Locations Provided

More Information

Additional Information:

Study Results This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	ACD2601g
Study First Received:	November 12, 2004
Last Updated:	November 14, 2005
ClinicalTrials.gov Identifier:	NCT00096603 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Genentech:

Moderate to severe plaque psoriasis

Study placed in the following topic categories:

Skin Diseases
Psoriasis
Skin Diseases, Papulosquamous

Additional relevant MeSH terms:

Skin Diseases
Psoriasis
Skin Diseases, Papulosquamous

ClinicalTrials.gov processed this record on September 10, 2009